Nasdaq GlobeNewswire

Summit Announces Key Appointments to Strengthen Research and Development Team

  • Dr David Roblin to combine Chief Operating Officer and Chief Medical Officer roles
  • Dr Anne Heatherington appointed Head of Clinical Development and Quantitative Sciences
  • Dr Dave Powell appointed Head of Research

Tonix Pharmaceuticals Presented Analyses of Potential Moderators of Treatment Response to U.S. FDA-Designated Breakthrough Therapy for PTSD, TNX-102 SL, in Phase 2 AtEase Study in Military-Related PTSD

 

NEW YORK, May 22, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health challenges, presented a poster on May 20, 2017, entitled “Phase 2 Multisite Double-Blind Placebo-Controlled Trial of TNX-102 SL in Military-Related Posttraumatic Stress Disorder: Mediators and Moderators of Treatment Response” (Poster No. 3001130) at the 72nd Annual Scientific Convention of the Society of Biological Psychiatry in San Diego. The poster can be found on the Scientific Presentations page on Tonix’s website. A moderator is a characteristic of study participants that is associated with a treatment response.

EDAP Announces CMS Approval of New Reimbursement Code for HIFU Ablation of the Prostate

  • Billing code will take effect July 1st, 2017

Arbutus Presents HBV Drug Combination Studies at ICAR

Combinations of Arbutus’ RNAi or Capsid Assets with Approved Drugs Demonstrate Complementary Activity
Dr. Michael J. Sofia, Arbutus’ Chief Scientific Officer, Awarded International Society of Antiviral Research Gertrude Elion Award

Crown Bioscience Announces Record Breaking Growth With First 2017 Quarter Results

SANTA CLARA, Calif., May 19, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, announces continued growth in 2017 with dramatic first quarter results.

Kraig Biocraft Laboratories Delivers First Dragon Silk Fiber Samples to US Army

ANN ARBOR, Mich., May 19, 2017 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (“Company”), the leading developer of spider silk based fibers, today announced that it has delivered the first samples of Dragon Silk to the US Army for independent testing.  The Company provided several samples of individual silk filaments as well as finished Dragon Silk thread for evaluation.

American Health Council Names Jeffrey Scifert, PhD to Industry Board

NEW YORK, May 18, 2017 (GLOBE NEWSWIRE) -- Dr. Jeffrey Scifert, Senior Engineering Program Manager at Medtronic, has been selected to join the Industry Board at the American Health Council. He will be sharing his knowledge and expertise in Healthcare Education, Workforce Development, Business, and Biologics R&D.

Organovo Presents New Preclinical Data on 3D Bioprinted Human Liver Tissues at World Advanced Therapies and Regenerative Medicine Congress

 

SAN DIEGO, May 18, 2017 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today presented new preclinical data showing extended survival and sustained functionality of its 3D bioprinted human liver tissue when implanted into diseased animal models. This data was presented at the World Advanced Therapies and Regenerative Medicine Congress in London by Benjamin Sheperd, Ph.D., Director of Therapeutics, at Organovo.

Myriad Genetics to Present Seven Studies at the 2017 American Society of Clinical Oncology Annual Meeting

 

SALT LAKE CITY, May 18, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it will present results from seven studies at the 2017 American Society of Clinical Oncology (ASCO) annual meeting to be held June 2 to 6, 2016 in Chicago, Ill.  Abstracts of the Company's presentations are currently available at: abstracts.asco.org

Amarin Announces Expanded Research Relationships and Studies to Help Improve Cardiovascular Care

BEDMINSTER, N.J. and DUBLIN, Ireland, May 18, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today three new studies it is coordinating with leading health organizations and physicians. These studies are described in abstracts presented this week at the National Lipid Association (NLA) 2017 Scientific Sessions in Philadelphia.

Data from Clinical Study of NewLink Genetics’ IDO Pathway Inhibitor, Indoximod, to Be Presented at the 22nd European Hematology Association Congress

 

AMES, Iowa, May 18, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that an abstract describing data from a clinical study of its IDO pathway inhibitor, indoximod, in combination with chemotherapeutic agents for patients with newly diagnosed acute myelogenous leukemia (AML), is now available on the website of the European Hematology Association (EHA) Annual Congress.

Xeris Pharmaceuticals Announces Closing of $30 Million Financing

 

CHICAGO, IL and AUSTIN, TX, May 17, 2017 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc., a specialty biopharmaceutical company focused on the development and commercialization of novel formulations of ready-to-use injectable drugs, today announced the closing of a $30 million financing.  The Series C financing was led by Redmile Group.  Other participants in the financing included current investors such as Deerfield Management Company, Palmetto Partners, Wild Basin Investments and Asahi-Kasei Corporation.  New investors in the financing included Bay City Capital, Merieux Développement and members of Xeris management.

Data from Clinical Studies of NewLink Genetics’ Two Distinct IDO Pathway Inhibitors to Be Presented at ASCO 2017

 

AMES, Iowa, May 17, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that abstracts from two clinical studies of its IDO pathway inhibitors, indoximod and navoximod (GDC-0919), used in combination with other agents, are now available on the website of the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.

New Clinical and Biomarker Data Validate Immune Design’s Lead Programs and Discovery Platforms

Data from CMB305 and G100 to be Presented at ASCO Annual Meeting in June 2017

Immune Design Reports First Quarter 2017 Financial Results and Provides Corporate Update

SEATTLE and SOUTH SAN FRANCISCO, May 17, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today reported financial results and a corporate update for the first quarter ended March 31, 2017.

Organovo Announces Release Date for Fiscal Fourth-Quarter 2017 Financial Results

 

SAN DIEGO, May 17, 2017 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, will host a conference call on Wednesday, June 7, 2017 at 5:00 p.m. Eastern Time (ET) to discuss the Company's fiscal fourth-quarter 2017 financial results.  In advance of the call on June 7, 2017, Organovo will issue its fiscal fourth-quarter 2017 earnings press release, which will be available at http://www.organovo.com.  To participate in the teleconference, callers can dial the following numbers:

Catalyst Pharmaceuticals to Present at the Antiepileptic Drug and Device Trials XIV Symposium

 

CORAL GABLES, Fla., May 17, 2017 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating neuromuscular and neurological diseases, today announced that the company will be presenting at the Antiepileptic Drug and Device Trials XIV symposium in Aventura, FL. Gary Ingenito, M.D., Ph.D., Chief Medical Officer, will provide an overview of the company’s CPP-115 program for the treatment of infantile spasms titled, “CPP-115 Progress in Refractory Infantile Spasms” on Friday, May 19th at 11:55 am ET.  The Company’s presentation materials will be available on the “Investors” section of the Company’s website, www.catalystpharma.com following the presentation.

Burcon NutraScience Engages Stonegate Capital Partners to Lead Investor Communications and Outreach Program

VANCOUVER, British Columbia, May 17, 2017 (GLOBE NEWSWIRE) -- Burcon NutraScience Corporation (TSX:BU) (NASDAQ:BUR) (“Burcon”) a leader in developing functionally and nutritionally valuable plant-based proteins, is pleased to announce today that it has engaged Texas-based Stonegate Capital Partners, to lead a new investor communications and outreach program. 

Fibrocell to Present at Inaugural Cell & Gene Exchange 2017

 

EXTON, Pa., May 17, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that John Maslowski, Chief Executive Officer, will present at the inaugural Cell & Gene Exchange 2017 on Monday, May 22 at 2:00 pm EDT at the Ronald Reagan Building in Washington, D.C. In addition, Mr. Maslowski will participate in a roundtable discussion, “Best Practices for Partnering with Disease Foundations and Patient Groups,” on Monday, May 22 at 3:15 p.m. EDT.

CytoDyn Treats First Patient with PRO 140 in Phase 2 Trial for Graft versus Host Disease

VANCOUVER, Washington, May 17, 2017 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, announces the treatment of the first patient in its Phase 2 clinical trial for Graft versus Host Disease (GvHD), its leading immunologic indication for PRO 140.